Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03757325 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
A Phase 1 study, sponsored by Denali Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03757325 is a Phase 1 study that has completed, run by Denali Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT03757325, a Phase 1 study, has completed, sponsored by Denali Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Alzheimer's disease when administered for 29 days in a cross-over design
Interventions
- DRUG Placebo
- DRUG DNL747
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-02-13 |
| Est. Completion | 2019-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03757325
The ClinicalTrials.gov registry entry for NCT03757325 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denali Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03757325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03757325 about?
NCT03757325 is a clinical study titled "Study to Evaluate DNL747 in Subjects With Alzheimer's Disease". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Alzheimer's disease when administered for 29 days in a cross-over design
What is the current status of trial NCT03757325?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-02-13. Estimated completion is 2019-12-05.
What interventions are being tested in trial NCT03757325?
The interventions under investigation include: Placebo (DRUG), DNL747 (DRUG).
Who is sponsoring clinical trial NCT03757325?
This trial is sponsored by Denali Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.